Vaxart Inc (NASDAQ: VXRT)’s stock price has plunge by 1116317relation to previous closing price of 0.56. Nevertheless, the company has seen a -11.51% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-13 that SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders.
Is It Worth Investing in Vaxart Inc (NASDAQ: VXRT) Right Now?
Company’s 36-month beta value is 1.16.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VXRT is 222.15M, and currently, short sellers hold a 6.61% ratio of that floaft. The average trading volume of VXRT on June 24, 2025 was 4.25M shares.
VXRT’s Market Performance
VXRT stock saw an increase of -11.51% in the past week, with a monthly gain of 24.28% and a quarterly increase of 13.95%. The volatility ratio for the week is 5.53%, and the volatility levels for the last 30 days are 9.57% for Vaxart Inc (VXRT). The simple moving average for the past 20 days is 16.70% for VXRT’s stock, with a -5.62% simple moving average for the past 200 days.
Analysts’ Opinion of VXRT
Many brokerage firms have already submitted their reports for VXRT stocks, with Oppenheimer repeating the rating for VXRT by listing it as a “Outperform.” The predicted price for VXRT in the upcoming period, according to Oppenheimer is $4 based on the research report published on August 15, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $12, previously predicting the price at $13. The rating they have provided for VXRT stocks is “Buy” according to the report published on December 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to VXRT, setting the target price at $15 in the report published on November 02nd of the previous year.
VXRT Trading at 31.06% from the 50-Day Moving Average
After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.41% of loss for the given period.
Insider Trading
Lo Steven, the President, Chief Exec Officer of Vaxart Inc, purchase 100,000 shares at $0.49 during a trade that took place back on May 19 ’25, which means that Lo Steven is holding 100,000 shares at $49,000 based on the most recent closing price.
Stock Fundamentals for VXRT
Current profitability levels for the company are sitting at:
- -0.89 for the present operating margin
- 0.17 for the gross margin
The net margin for Vaxart Inc stands at -1.23. The total capital return value is set at -0.7. Equity return is now at value -114.74, with -47.02 for asset returns.
Based on Vaxart Inc (VXRT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -36.15.
Currently, EBITDA for the company is -54.87 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 2.56. The receivables turnover for the company is 2.94for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
In a nutshell, Vaxart Inc (VXRT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
